JP2010513523A5 - - Google Patents

Download PDF

Info

Publication number
JP2010513523A5
JP2010513523A5 JP2009542923A JP2009542923A JP2010513523A5 JP 2010513523 A5 JP2010513523 A5 JP 2010513523A5 JP 2009542923 A JP2009542923 A JP 2009542923A JP 2009542923 A JP2009542923 A JP 2009542923A JP 2010513523 A5 JP2010513523 A5 JP 2010513523A5
Authority
JP
Japan
Prior art keywords
compound
nhc
independently
cycloalkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009542923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513523A (ja
JP5528812B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/026064 external-priority patent/WO2008079292A1/en
Publication of JP2010513523A publication Critical patent/JP2010513523A/ja
Publication of JP2010513523A5 publication Critical patent/JP2010513523A5/ja
Application granted granted Critical
Publication of JP5528812B2 publication Critical patent/JP5528812B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009542923A 2006-12-20 2007-12-19 複素環式化合物ならびに炎症、血管形成および癌の治療におけるこれらの使用 Expired - Fee Related JP5528812B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87628306P 2006-12-20 2006-12-20
US60/876,283 2006-12-20
PCT/US2007/026064 WO2008079292A1 (en) 2006-12-20 2007-12-19 Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer

Publications (3)

Publication Number Publication Date
JP2010513523A JP2010513523A (ja) 2010-04-30
JP2010513523A5 true JP2010513523A5 (enExample) 2011-01-20
JP5528812B2 JP5528812B2 (ja) 2014-06-25

Family

ID=39281186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009542923A Expired - Fee Related JP5528812B2 (ja) 2006-12-20 2007-12-19 複素環式化合物ならびに炎症、血管形成および癌の治療におけるこれらの使用

Country Status (8)

Country Link
US (1) US8338455B2 (enExample)
EP (1) EP2118088B1 (enExample)
JP (1) JP5528812B2 (enExample)
AU (1) AU2007338793B2 (enExample)
CA (1) CA2672903C (enExample)
ES (1) ES2387471T3 (enExample)
MX (1) MX2009006543A (enExample)
WO (1) WO2008079292A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55634B1 (sr) 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaril substituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
HUE043732T2 (hu) 2007-06-13 2019-09-30 Incyte Holdings Corp Januskináz gátló hatású (R)-3-(4-(7H pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropánnitril sók alkalmazása
ES2389992T3 (es) 2007-11-02 2012-11-05 Vertex Pharmaceuticals Incorporated Derivados de [1H-pirazolo[3,4-b]piridin-4-il]-fenilo o -piridin-2-ilo como proteína cinasa c-theta
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
CA2747170C (en) * 2008-12-19 2017-07-18 Abbott Laboratories Tetrahydroisoquinoline derivatives and their uses to treat cancers and autoimmune disorders
EP2432555B1 (en) * 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
KR20120030447A (ko) 2009-05-22 2012-03-28 인사이트 코포레이션 Jak 저해물질로서 3-[4-(7h-피롤로[2,3-d]피리미딘-4-일)-1h-피라졸-1-일]옥탄- 또는 헵탄-니트릴
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TWI531572B (zh) 2010-03-10 2016-05-01 英塞特公司 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
US20110288107A1 (en) 2010-05-21 2011-11-24 Bhavnish Parikh Topical formulation for a jak inhibitor
PH12013501001A1 (en) 2010-11-19 2019-09-02 Incyte Holdings Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
AU2012273164B2 (en) 2011-06-20 2015-05-28 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
CN103619818A (zh) 2011-06-20 2014-03-05 纳幕尔杜邦公司 用于治疗蠕虫感染的杂环化合物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
KR20140094026A (ko) 2011-11-28 2014-07-29 이 아이 듀폰 디 네모아 앤드 캄파니 N-(4-퀴놀리닐메틸) 설폰아미드 유도체 및 구충제로서의 이의 용도
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
NZ707495A (en) 2012-11-01 2019-01-25 Incyte Holdings Corp Tricyclic fused thiophene derivatives as jak inhibitors
CR20190073A (es) 2012-11-15 2019-04-25 Incyte Holdings Corp FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265)
WO2014099837A1 (en) 2012-12-18 2014-06-26 E. I. Du Pont De Nemours And Company Sulfonamide anthelmintics
SMT202100694T1 (it) 2013-03-06 2022-03-21 Incyte Holdings Corp Procedimenti e intermedi per produrre un inibitore di jak
CA2920108C (en) 2013-08-07 2022-07-05 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
CA2947418A1 (en) 2014-04-30 2015-11-05 Incyte Corporation Processes of preparing a jak1 inhibitor and new forms thereto
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
EP3746429B1 (en) 2018-01-30 2022-03-09 Incyte Corporation Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
MX2020010322A (es) 2018-03-30 2022-11-30 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
CN115397412B (zh) * 2020-04-17 2025-03-25 伊赛恩特制药公司 Mas相关g蛋白受体x4的调节剂及相关产物和方法
CA3182012A1 (en) * 2020-05-08 2021-11-11 Georgiamune Llc Akt3 modulators
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903196A1 (en) 1989-09-05 1991-03-13 Searle & Co Substituted n-benzylpiperidine amides
US6143764A (en) 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
KR100838617B1 (ko) 1999-02-10 2008-06-16 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
ES2250186T3 (es) 1999-09-10 2006-04-16 MERCK & CO., INC. Inhibidores de tirosina quinasa.
EP1506962B1 (en) 2000-10-20 2008-07-02 Eisai R&D Management Co., Ltd. Nitrogen-containing aromatic heterocycles
FR2816940A1 (fr) * 2000-11-23 2002-05-24 Lipha Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation
AU2002313249B2 (en) 2001-06-22 2008-08-21 Kirin Pharma Kabushiki Kaisha Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same
AU2005207946A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
EA011402B1 (ru) 2004-01-23 2009-02-27 Эмджен Инк. Азотсодержащие гетероциклические производные и их фармацевтические применения
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use

Similar Documents

Publication Publication Date Title
JP2010513523A5 (enExample)
JP2018507214A5 (enExample)
JP2016523974A5 (enExample)
JP2013544261A5 (enExample)
JP2013510120A5 (enExample)
JP2015506348A5 (enExample)
JP2013512903A5 (enExample)
JP2013544846A5 (enExample)
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
JP2016530283A5 (enExample)
JP2019537570A5 (enExample)
JP2011001339A5 (enExample)
RU2009123930A (ru) Химические соединения 637: пиридопиримидиндионы в качестве ингибиторов pde4
RU2014130125A (ru) Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
JP2011079828A5 (enExample)
WO2016203404A1 (en) Compounds and compositions for inhibiting the activity of shp2
JP2014503567A5 (enExample)
RU2016130932A (ru) Производные хинолона как ингибиторы рецептора фактора роста фибробластов
JP2013533879A5 (enExample)
JP2016528197A5 (enExample)
JP2014518882A5 (enExample)
JP2014513704A5 (enExample)
JP2015504061A5 (enExample)
JP2013520443A5 (enExample)
JP2014528467A5 (enExample)